Theravance Biopharma, Inc. (TBPH) fair value analysis
Nasdaq · Updated 2026-10-19
TBPH price how computed
Valuation status
Awaiting full valuationTBPH does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $17.03
- Sector
- Healthcare
- 12-month range
- $13.57–$20.74
- Market cap
- $884M
- From 52-week high
- -17.9%
- Shares outstanding
- 51.9M
- Rank in Healthcare by quality score
- #33 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Theravance Biopharma, Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule medicines. The company operates in the United States and conducts research and development activities targeting respiratory, cardiovascular, and other therapeutic areas.
TBPH currently ranks #33 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $884M
- P/E (trailing)
- 95x
- Revenue (TTM)
- $104M
- Net margin
- 51.6%
- EPS (TTM)
- $0.18
- Gross margin
- 93.0%
- Debt / equity
- 0.13
- Revenue growth (3-yr avg)
- 10.7%
- Shares outstanding
- 51.9M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
- DCF cross-check
- Undervalued
Technicals how computed
- RSI (14-day)
- 43 · neutral
- 50-day average
- $17.02
- 200-day average
- $17.07
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Earnings how computed
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▼ miss (-50.0%)
2026-03 ▼ miss (-88.9%)
2025-12 ▼ miss (-94.1%)
2025-09 ▲ beat (+180.0%)
2025-06 ▲ beat (+61.2%)
2025-03 ▼ miss (-88.9%)
2024-12 ▲ beat (+39.9%)
2024-09 ▲ beat (+40.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 0 buy · 5 hold · 0 sell (5 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $17.7
- Target vs last price
- +3.9%
What our data shows for TBPH
- Our model validated 5 trailing price-to-earnings windows for TBPH, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $13.57–$20.74.
- The 14-day relative strength index sits at a neutral 43.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- TBPH's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent TBPH news
TickrTrends' derived news-sentiment signal for TBPH is currently leaning positive, computed from recent coverage.
- Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma (manilatimes.net, 2026-10-19)
- Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Eyes Growth in COPD Market (gurufocus.com, 2026-09-28)
- Zymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - Slideshow (NASDAQ:ZYME) 2026-09-28 (seekingalpha.com, 2026-09-28)
More TBPH news
- TBPH Suspended by BTIG - Analyst Rating Remains Neutral (gurufocus.com, 2026-09-24)
What people are saying
Follow the TBPH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TBPH's quality grade improved significantly this week, rising from C to A according to TickrTrends' derived indicators. This upgrade suggests meaningful improvement in the company's fundamental characteristics within the Healthcare sector. The valuation verdict remains under review as a full assessment awaits completion.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is TBPH stock undervalued?
TBPH does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is TBPH's TickrTrends verdict?
TBPH is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does TBPH compare to other Healthcare stocks?
TBPH ranks #33 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is TBPH overbought or oversold?
TBPH's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does TBPH usually beat earnings estimates?
Over its last 8 reported quarters TBPH beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TBPH?
Of 5 analysts covering TBPH, 0 rate it a buy, 5 a hold and 0 a sell - hold-leaning, with a consensus price target of $17.7 (+3.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.